120739-87-9

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Pyridine, 4-(chloromethyl)-2,6-dimethyl(9CI) serves as a crucial intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows it to be a versatile building block for the development of new drugs and agricultural chemicals, contributing to advancements in healthcare and agriculture.
Used in Rubber Production:
In the rubber industry, Pyridine, 4-(chloromethyl)-2,6-dimethyl(9CI) is utilized to enhance the properties of rubber, improving its performance and durability. Its incorporation into rubber formulations can lead to the creation of rubber products with specific characteristics required for various applications.
Used in Dye Manufacturing:
Pyridine, 4-(chloromethyl)-2,6-dimethyl(9CI) is also employed in the production of dyes, where it contributes to the development of a wide range of colorants used in various industries, including textiles, plastics, and printing inks. Its presence in dye manufacturing aids in creating dyes with improved properties, such as colorfastness and stability.
Used in the Synthesis of Other Organic Compounds:
Beyond its applications in specific industries, Pyridine, 4-(chloromethyl)-2,6-dimethyl(9CI) is a valuable intermediate in the synthesis of a broad spectrum of organic compounds. Its reactivity and structural features make it suitable for use in organic chemistry, leading to the creation of new compounds with diverse applications.

Upstream product

• 3376-50-9 2,4,6-trimethyl-pyridine 1-oxide 
• 18088-01-2 2,6-dimethyl-4-pyridinemethanol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 130138-46-4 (2,6-dimethylpyridin-4-yl)acetonitrile 

Relevant academic research and scientific papers

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and

NEW COMPOUNDS V

The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associate

PYRIDYLISOXAZOLE DERIVATIVE

This invention offers isoxazole derivatives represented by the following formula (I) in which R1 and R2 each stands for hydrogen, lower alkyl, amino and the like; R3 stands for substituted or unsubstituted aryl or hetero a

Facile and Selective Synthesis of Chloromethylpyridines and Chloropyridines Using Diphosgene/Triphosgene

Diphosgene and triphosgene in the presence of amines were found to be an excellent chlorinating agents with high selectivity for the preparation of chloromethylpyridines and chloropyridines from picoline-N-oxides and pyridine-N-oxides respectively.

Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)

The present application describes novel bicyclic lactam derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein A, B, C, D, R1, and R2 are defined in the present specification, which are useful as metallo

Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones

The present invention relates to optionally substituted pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones or optionally substituted pyrido[2,3-d]pyrimidine-2(1H,3H)-ones, i.e., compounds of Formula I: STR1 wherein: Y is --CH2 -- or --C(O)--; R1 is hydrogen or --(CH2)n --R7, wherein: R7 is aryl or heteroaryl, and n is 1 or 2, provided that when Y is --C(O)--, R7 is heteroaryl; and R2, R3, R4, R5 and R6 are hydrogen, or one is selected from lower alkyl, halo, carboxy, methoxycarbonyl, carbamoyl, methylcarbamoyl, di-methylcarbamoyl, methylcarbonyl, methylthio, methylsulfinyl, methylsulfonyl, hydroxymethyl, amino, trifluoromethyl, cyano or nitro; or R2, R3, R4 and R5 are independently selected from hydrogen, lower alkyl, nitro, chloro, fluoro, methoxycarbonyl or methylcarbonyl, provided at least one is hydrogen, and R6 is hydrogen; or a pharmaceutically acceptable ester, ether or salt thereof.